Morie A Gertz MD MACP
Hematologic Oncology
Professor of Hematology & Oncology, Mayo Medical School
Join to View Full Profile
200 1st Street SWRochester, MN 55905
Dr. Gertz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1979 - 1983
Rush University Medical CenterResidency, Internal Medicine, 1976 - 1979
Ascension Illinois/Saint Joseph (Chicago)Residency, Internal Medicine, 1976 - 1976
Loyola University Chicago Stritch School of MedicineClass of 1975
Northwestern UniversityB.A., Arts and Sciences, With Highest Distinction, 1972
Certifications & Licensure
AZ State Medical License 1989 - 2026
MN State Medical License 1979 - 2026
IL State Medical License 1977 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 2 Certification Mayo Clinic Incorporate Lab Results, Mayo Clinic, 2014-2017
- CMS Meaningful Use Stage Stage 2 Certification Centricity Patient Online, GE Healthcare, 2014-2017
- CMS Meaningful Use Stage Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2017
Clinical Trials
- High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse Start of enrollment: 1993 Jun 01
- High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 1998 Nov 16
- 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 1999 Apr 01
Publications & Presentations
PubMed
- POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.Saurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, Damien Roos-Weil, Dirk R Larson
Blood Advances. 2026-01-07 - Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma.Saurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, Horatiu Olteanu, Francis Buadi
Blood Cancer Journal. 2026-01-03 - Proteomic shifts post-plasma cell therapy in AL amyloid plaques and potential implications for light chaindirected anti-fibril monoclonal antibodies.Matthew J Rees, Surendra Dasari, Ellen D McPhail, Angela Dispenzieri, Cristine M Charlesworth
Haematologica. 2026-01-01
Journal Articles
- Systemic Amyloidosis Recognition, Prognosis, and TherapyMorie A Gertz, Angela Dispenzieri, JAMA
- Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple MyelomaS Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
- Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell TransplantationNelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
Books/Book Chapters
Abstracts/Posters
- Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin DiseaseMorie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution ExperienceMorie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISHMorie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Adult Clinical Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Training Program DirectorsÍ Workshop61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Authored Content
- Does Stem Cell Transplantation Provide Enough Benefit for Newly Diagnosed Multiple Myeloma Patients?June 2022
- Systemic Amyloidosis Recognition, Prognosis, and TherapyJuly 2020
- Systemic Amyloidosis Recognition, Prognosis, and TherapyJuly 2020
Press Mentions
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 MeetingNovember 3rd, 2022- Mayo Clinic Research in the News — 4/26/2021April 26th, 2021
- Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-cs3) in Hereditary Transthyretin-Mediated Amyloid PolyneuropathyFebruary 26th, 2021
Grant Support
- Phase 3 Stem Cell Transplant For Light Chain AmyloidosisNational Cancer Institute2005–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
